A key element of the U.S. Food and Drug Administration’s (FDA’s) mission is focused on helping to ensure that all products the agency regulates, which includes drugs available to consumers, are of high quality and safe.
Ensuring greater accountability in our nation’s drug supply chain is major part of these efforts.
Towards that end, the agency has launched a new pilot project in which participants representing the drug supply chain (e.g., manufacturers, repackagers and other stakeholders) can pilot the use of innovative and emerging approaches for enhanced tracing and verification of prescription drugs in the U.S. to ensure suspect and illegitimate products do not enter the supply chain.
FDA Seeking Participants for Track-and-Trace Pilot Projects
The FDA is seeking eligible entities to apply to participate in the program.
The pilot will inform the development of the enhanced electronic, interoperable track-and-trace system for industry set to go into effect in 2023 as part of the Drug Supply Chain Security Act, using technologies that may become part of our enhanced expectations for reliable track-and-trace systems.
(The US FDA for short, has announced the launch of an open blockchain pilot program. Scott Gottlieb Commissioner of the FDA decided to use the technology specifically for tracking the provenance of pharmaceuticals. Courtesy of Bloxlive and YouTube. Posted on Feb 13, 2019.)
The new system will be aimed at reducing diversion of drugs distributed domestically and will help keep counterfeit drugs from entering the supply chain, and ultimately, reaching patients.
“As part of our ongoing efforts to protect our nation’s drug supply, today, we’re giving industry an opportunity to test new technologies that can help spur greater accountability for participants in the supply chain and improve our ability to trace prescription drugs at every point in the distribution chain,” explained former FDA Commissioner Scott Gottlieb, M.D. prior to submitting his resignation earlier this month.
“Using new innovations, we believe we can improve the overall security of our closed system and improve our ability to prevent the introduction of illegitimate products, better detect the introduction of illegitimate products, and enable stakeholders and the FDA to respond more rapidly when such products are found.”
“We recognize that tracking and tracing products is critical to industry’s ability to detect and remove potentially dangerous drugs from the drug supply chain.”
“This pilot is one of many steps we’re taking to foster innovative ways to improve the security of the drug supply.”
“We’re also focused on making improvements across the other products we regulate, especially related to food and our ability to address foodborne outbreaks.”
“We’re invested in exploring new ways to improve traceability, in some cases using the same technologies that can enhance drug supply chain security, like the use of blockchain.”
“To advance these efforts, the FDA recently recruited Frank Yiannas, an expert on the use of traceability technologies in global food supply chains.”
“He’ll be working closely with me on ways for the FDA to facilitate the expansion of such methods, such as blockchain technology, to further strengthen the U.S. food supply.”
“Under his leadership, we’ll continue to leverage all tools available to ensure greater accountability.”
“For the drug track-and-trace system, our goals are to fully secure electronic product tracing, which provides a step-by-step account of where a drug product has been located and who has handled it; establish a more robust product verification to ensure that a drug product is legitimate and unaltered; and to make sure that any party involved in handling drugs in the supply chain must have the ability to spot and quarantine and investigate any suspect drug.”
“We’re committed to staying at the forefront of new and emerging technologies and how they might be used to create safer, smarter and more trusted supply chains to better protect consumer safety and ensure the integrity of the high quality of products they deserve.”
The DSCSA pilot project program is intended to help identify and evaluate the most efficient processes to comply with and apply drug supply chain security requirements, and will aid in identifying attributes the system will need for enhanced product tracing and verification, as well as electronic means to share the information.
The FDA is committed to sharing new approaches considered through this program with the broader drug supply chain community on the agency’s website, with a goal of ensuring that all parties can be apprised of its progress and take advantage of any shared learning.
The FDA has previously taken steps to advance the development and adoption of technologies that can help identify and properly trace prescription drugs as they move through the supply chain. For example, the FDA recently issued draft guidance on the use of product identifiers with a unique serial number to improve verification down to the package level.
Additionally, the FDA has provided draft guidance for verification systems to quarantine and investigate suspect and illegitimate drugs.
Enhanced verification and tracing in the supply chain can translate to a more rapid response by industry and the FDA when an illegitimate product is found.
